HCG

Human chorionic gonadotropin (HCG) is a glycoprotein hormone commonly used to stimulate testosterone production and support fertility. People typically run it at daily doses around 200 µg to 6.3 mg, with the community modal near 6.3 mg and clinician guidance often citing 250 µg subcutaneously each day. Injection-site reactions, histamine/flush, and edema or fluid retention have each been reported once, making them uncommon but noted occurrences.

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.54.82.83.72.91.0

Research Evidence

Evidence shape

HCG has Phase 3 RCT-grade clinical evidence for Infertility. Off-label / exploratory data exists for 58 additional indications (Ovulation Induction; Idiopathic Hypogonadotropic Hypogonadism). 11 trials were withdrawn or terminated — surfaced below as signal of absence, not omitted.

Depthhow much
148 registered trials
95 completed · 25 with posted results · 14 recruiting / active · combined n=3523
Breadthhow many areas
75 indications mapped
11 with results · 58 thin / exploratory · 1 animal-only · 56 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
7 blinded with results · 55 distinct sponsors · AE rows aggregated from 7 trials · 32 linked publications on registered trials
Breadth and depth158 rows captured
Human
direct clinical signal
148
Animal
translational support
3
In vitro
mechanistic support
7
HighMediumLow

Anecdotal efficacy

HCG side effects

Clinical research side effects

Anecdotal side effects

1
--
20 mg
$75.00
$3.75/mg
2
GB
10 mg
$53.69
$5.37/mg
3
Australia
10 mg
$76.50
$7.65/mg
4
--
10 mg
$95.00
$9.5/mg
5
US
5 mg
$58.00
$11.6/mg
6
--
0.5 mg
$49.99
$99.98/mg

price offers can be sorted by column

HCG dosing & protocol

How HCG is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
0
2 mg
4 mg
6 mg
8 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

In the research trials tier for HCG, no completed trial was identified, so dosing information for this peptide is not reliably extracted.

Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
250 µg
typical
0
2 mg
4 mg
6 mg
8 mg
across 1 dosed source · darker = more agree
By reported cadence
Daily250 µg · n=1
Frequency
daily
Route
subQ

Based on a single source, the clinician practice tier reports a subcutaneous dose of 250 micrograms taken daily, with no reported cycling or weight‑based adjustment.

1 source
Anecdotal
Community-reported real-world use · n = 4
Typical dose
6.3 mg200 µg – 6.3 mg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 4 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mixed
Route
subQ

Community reports show HCG dosing ranging from 200 mcg to 6.3 mg, with individual users taking it daily, three times weekly, weekly, or on an unspecified schedule.

4 sources

Regulatory safety notes

Warnings and precautions
  • WARNINGS: HCG should be used in conjunction with human menopausal gonadotropins only by physicians experienced with infertility problems who are familiar with the criteria for patient selection, contraindications, warnings, precautions and adverse reactions d…
  • The principal serious adverse reactions are: (1) Ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain and/or pleural effusion, (2) Rupture of ovarian cysts with resultant hemoperitoneum, (3) Multiple births and (4)…
Contraindications
  • CONTRAINDICATIONS: Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG.